Publications by authors named "Rosa Caputo"

Claim this Profile
A
A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action.
Vincenzo Damiano, Sonia Garofalo, Roberta Rosa, Roberto Bianco, Rosa Caputo

Clin Cancer Res· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.
Vincenzo Damiano, Rosa Caputo, Sonia Garofalo, Roberto Bianco, Roberta Rosa

Proc Natl Acad Sci U S A· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Vincenzo Damiano, Rosa Caputo, Roberto Bianco, Francesco P D'Armiento, Antonio Leonardi

Clin Cancer Res· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.
Davide Melisi, Rosa Caputo, Vincenzo Damiano, Roberto Bianco, Bianca Maria Veneziani

Endocr Relat Cancer· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.
Vincenzo Damiano, Davide Melisi, Cataldo Bianco, David Raben, Rosa Caputo

Clin Cancer Res· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Roberto Bianco, Roberta Caputo, Rosa Caputo, Vincenzo Damiano, Sabino De Placido

Clin Cancer Res· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Fortunato Ciardiello, Roberto Bianco, Roberta Caputo, Rosa Caputo, Vincenzo Damiano

Clin Cancer Res· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism.
Rosa Caputo, Concetta Tuccillo, Barbara A Manzo, Raffaele Zarrilli, Giampaolo Tortora

Clin Cancer Res· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
Fortunato Ciardiello, Rosa Caputo, Vincenzo Damiano, Roberta Caputo, Teresa Troiani

Clin Cancer Res· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Giampaolo Tortora, Rosa Caputo, Vincenzo Damiano, Davide Melisi, Roberto Bianco

Clin Cancer Res· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
Giampaolo Tortora, Rosa Caputo, Vincenzo Damiano, Roberta Caputo, Teresa Troiani

Clin Cancer Res· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
Cataldo Bianco, Giampaolo Tortora, Roberto Bianco, Roberta Caputo, Bianca Maria Veneziani, Rosa Caputo

Clin Cancer Res· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
Fortunato Ciardiello, Rosa Caputo, Gaetano Borriello, Donatella Del Bufalo, Annamaria Biroccio

Int J Cancer· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis